Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2006 2
2007 3
2008 2
2009 3
2010 1
2011 7
2012 12
2013 11
2014 11
2015 12
2016 11
2017 20
2018 17
2019 22
2020 41
2021 28
2022 18
2023 22
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Behrens F. Kristensen LE, et al. Among authors: soliman am. Ann Rheum Dis. 2022 Feb;81(2):225-231. doi: 10.1136/annrheumdis-2021-221019. Epub 2021 Dec 15. Ann Rheum Dis. 2022. PMID: 34911706 Free PMC article. Clinical Trial.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA. Stein Gold LF, et al. Among authors: soliman am. Br J Dermatol. 2023 Oct 25;189(5):540-552. doi: 10.1093/bjd/ljad252. Br J Dermatol. 2023. PMID: 37488811 Clinical Trial.
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, Amin AZ, Liu J, Wu T, Azam T, Stakias V, Espaillat R, Sinvhal R, Soliman AM, Pang Y, Chen MM, Lebwohl MG. Papp KA, et al. Among authors: soliman am. J Am Acad Dermatol. 2023 Dec;89(6):1149-1158. doi: 10.1016/j.jaad.2023.07.1024. Epub 2023 Aug 6. J Am Acad Dermatol. 2023. PMID: 37553030 Free article. Clinical Trial.
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Östör A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, Alperovich G, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Kivitz A. Östör A, et al. Among authors: soliman am. Ann Rheum Dis. 2022 Mar;81(3):351-358. doi: 10.1136/annrheumdis-2021-221048. Epub 2021 Nov 23. Ann Rheum Dis. 2022. PMID: 34815219 Free PMC article. Clinical Trial.
Infections and edema.
Linkov G, Soliman AM. Linkov G, et al. Anesthesiol Clin. 2015 Jun;33(2):329-46. doi: 10.1016/j.anclin.2015.02.005. Anesthesiol Clin. 2015. PMID: 25999006 Review.
ACE-inhibitor-related angioedema.
Chan NJ, Soliman AM. Chan NJ, et al. Among authors: soliman am. Ear Nose Throat J. 2015 Jun;94(6):207-8. doi: 10.1177/014556131509400602. Ear Nose Throat J. 2015. PMID: 26053974 Free article. No abstract available.
Laryngeal chondrosarcoma.
Chan NJ, Fundakowski C, Soliman AM. Chan NJ, et al. Among authors: soliman am. Ear Nose Throat J. 2018 Jun;97(6):E41-E42. doi: 10.1177/014556131809700605. Ear Nose Throat J. 2018. PMID: 30036424 Free article. No abstract available.
220 results